Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease
DIGITAL.CSIC (Spanish National Research Council (CSIC)) May 12, 2026 Javier Calleja‐conde, Víctor Echeverry‐alzate, Marina Sanz-Sancristóbal et al.
Parkinson's disease involves progressive loss of dopamine-producing neurons in the nigrostriatal pathway, along with brain inflammation. Current medications only manage symptoms. This preclinical study tested N,N-dimethyltryptamine (DMT), the active compound in ayahuasca, which activates serotonin 5-HT2A receptors (causing hallucinogenic effects) and sigma-1 receptors linked to neuroprotection. DMT treatment produced molecular changes in the nigrostriatal pathway indicating reduced neuroinflammation and preserved neurons. Behavioral tests also showed symptom improvement. These results suggest DMT may modify disease progression in Parkinson's disease, supporting further research.